Protocol Ledger

NCT04852679 · Phase III · COMPLETED

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Interventional Phase III clinical trial protocol NCT04852679 sponsored by Ipsen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-24 Enrollment: 43 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04852679
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)43 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04852679
Protocol FieldVerified Registry Value
NCT IdentifierNCT04852679
Consolidated Lead SponsorIpsen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment43 participants (ACTUAL)
Registered Start Date2021-05-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI